Theorem Clinical Research

Articles Published in 2008

Covance Posts 11% Revenue Growth

Thursday, October 23, 2008 04:05 PM

Although Princeton, N.J., CRO Covance experienced a number of third quarter cancellations and project delays, the company posted 11.1% revenue growth for the third quarter. Profit rose 15% to $51.1 million, or $0.80 per diluted share.

More... »

PPD 3Q Earnings Up, Cuts 2008 Guidance

Wednesday, October 22, 2008 09:04 AM

PPD, a contract research organization (CRO), reported third quarter revenue increased 11.6% to $398.5 compared with $357.2 million for the third quarter of 2007. Diluted earnings per share jumped 34% to $0.43 per share.

More... »

ICON's Q3 Revenues Up 35%

Tuesday, October 21, 2008 10:17 AM

Dublin, Ireland-based contract research organization (CRO) ICON released third quarter financial results that show a 35% increase in revenues compared with the same period last year. Net revenues for the quarter were $225.5 million, compared with $166.9 million in the third quarter of 2007. Year-to-date net revenues are up 43.4% to $645.2 million, exceeding net revenues achieved in all of 2007, according to a company release. Operating profits the first nine months of 2008 were $73 million. Net income jumped 46% to $21.4 million or 35 cents per share on a diluted basis, compared with $14.5 million or 24 cents per share in the prior year's quarter.

More... »

JDRF Names PPD Preferred Provider

Monday, October 20, 2008 09:00 AM

The Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of type 1 diabetes research, has teamed up with global contract research organization (CRO) PPD in a unique partnership designed to improve clinical research for type 1 diabetes.

More... »

C-TASC to Help FDA Improve NDA Review Process

Thursday, October 16, 2008 12:00 PM

Clinical Trials & Surveys Corp (C-TASC), a clinical trials solutions company, will assist the U.S.Food and Drug Administration (FDA) Centers for Quality Assurance and Biostatistics to develop new methods and procedures for evaluating all New Drug Applications submitted for FDA approval. Under the $5.5 million base contract, C-TASC will use components of its StudyCTMS study management software application to customize a solution for the FDA that will standardize how clinical trial data for new therapies will be presented and reviewed. C-TASC statisticians will also work with FDA staff to perform some of the data preparations and analyses for these reviews. StudyCTMS is C-TASC’s proprietary web-based data management solution that enables clinical trials managers to easily develop and manage clinical studies and deliver the accumulated data and metadata in an easy-to-read and FDA-acceptable format.

More... »

Charles River Labs to Open Preclinical Facility in Shanghai

Wednesday, October 15, 2008 12:41 PM

Preclinical research powerhouse Charles River Laboratories is expanding its global reach with a new 60,000-square-foot facility in Shanghai, China.

More... »

Conflict of Interest Case Could Change Disclosure Rules

Tuesday, October 14, 2008 06:37 AM

The congressional investigation into an influential psychiatrist’s failure to disclose more than a million dollars in drugmaker payments is the latest in a spate of conflict-of-interest investigations that may force changes in the way financial disclosures are handled.

More... »

CenterWatch Releases Special Report on Clinical Trial Development in Central and Eastern Europe

Friday, October 10, 2008 11:48 AM

CenterWatch, a global source for clinical trials information, today announced the release of its latest report, Central and Eastern Europe: Outsourcing Trends and Growth Opportunities in Clinical Trials. The report explores the evolution of this region that has seen its growth in the industry triple in the last five years, making it the largest area for global clinical trial initiations outside of North America and Western Europe.

More... »

Phase Forward Founder Steps Down

Thursday, October 9, 2008 01:00 PM

Dr. Paul Bleicher, chairman and founder of Waltham, Mass.-based eClinical technology company Phase Forward, will step down from his day-to-day operational responsibilities at the end of October. Phase Forward president and CEO Robert Weiler will also assume Bleicher’s role as chairman of the company’s board of directors, of which Bleicher will remain a member.

More... »

Averion Expands European Operations

Wednesday, October 8, 2008 01:06 PM

Averion, a contract research organization (CRO) specializing in oncology, cardiovascular diseases and medical devices, has expanded its European operations by opening an office in the Czech Republic.

More... »

CenterWatch Data Library



Browse by:


October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs